esRAGE与早期非糖尿病慢性肾脏病患者左心室肥厚的相关性研究
2016-01-11李玲玲,芝敏,张蕾等
esRAGE与早期非糖尿病慢性肾脏病患者左心室肥厚的相关性研究
李玲玲1, 芝敏2, 张蕾2, 张鹏2
(新疆医科大学第五附属医院1超声诊断科,2肾病科, 乌鲁木齐830011)
摘要:目的探讨血清内源性可溶性终末糖基化产物受体(esRAGE)水平与早期非糖尿病慢性肾脏病(CKD)患者左心室肥厚(LVH)的关系。方法选择2012年12月-2013年7月于新疆医科大学第五附属医院肾病科住院与门诊就诊的CKD 1~3期患者70例为CKD组,并选取同期健康体检者50例为对照组,根据心脏彩超结果计算所得左室质量指数(LVMI),将患者分为慢性肾脏病伴左室肥厚组(CKD-LVH组)与慢性肾脏病非左室肥厚组(CKD-NLVH组),采用酶联免疫吸附法测定血清esRAGE水平,分析esRAGE水平与慢性肾衰竭患者左心室肥厚的相关性。结果CKD 组收缩压、LVMI、血糖、血磷、血清esRAGE水平均高于对照组(P<0.05),而血红蛋白、肌酐、GFR水平均低于对照组(P<0.05)。CKD-LVH 组esRAGE为(0.70±0.31) ng/mL,明显低于CKD-NLVH组的(1.40±0.99) ng/mL (P<0.05)。CKD组esRAGE水平与左室质量指数(LVMI)呈负相关(r=-0.362, P<0.05),Logistic回归分析显示esRAGE与早期CKD患者左心室肥厚具有相关性[OR=0.18,95%CI(0.04~0.82),P<0.05]。结论esRAGE在CKD早期即可增高,其水平与LVMI呈负相关, esRAGE水平的升高可能是CKD患者左心室肥厚的保护性因素。
关键词:esRAGE; 慢性肾脏病; 左心室肥厚
中图分类号:R54文献标识码:A
doi:10.3969/j.issn.1009-5551.2015.05.018
[收稿日期:2014-09-22]
Correlation between endogenous secretory soluble form of advanced glycation
end products receptor and left ventricular hypertrophy in patients with early
chronic kidney disease
LI Lingling1, ZHI Min2, ZHANG Lei2, ZHANG Peng2
(1DepartmentofUltrasound,2DepartmentofNephrology,TheFifthAffiliatedHospitalof
XinjiangMedicalUniversity,Urumqi830011,China)
Abstract:ObjectiveTo research the association of the level of endogenous secretory soluble form of advanced glycation end products receptor (esRAGE) with left ventricular hypertrophy in patients with early chronic kidney disease (CKD). MethodsBetween December 2012 and July 2013, 70 cases with early chronic kidney disease were divided into 2 groups: patients with left ventricular hypertrophy (CKD-LVH group) and patients without left ventricular hypertrophy (CKD-NLVH group). Meanwhile, 50 healthy subjects were as control group. all these patients were tested the level of esRAGE and creatinine. The cardiac lumen diameters were measured by echocardiography and left ventricular mass index(LVMI) was calculated. ResultsThe level of esRAGE in CKDgroup was significantly higher than that of control (P<0.05). Moreover, it in CKD-LVH group was lower than CKD-NLVH group. EsRAGE was related inversely with LVMI (P<0.05). ConclusionEsRAGE increased in patients with early chronic kidney disease. Maybe it can partly prevent chronic kidney disease patients from left ventricular hypertrophy.
Key words: esRAGE; chronic kidney disease; left ventricular hypertrophy
心血管疾病是慢性肾脏病的主要死因,而左室肥厚是慢性肾脏病患者最重要及常见的心血管结构改变,也是肾脏替代治疗患者死亡率的预测指标。近年来的研究表明,慢性肾脏病患者体内终末糖基化产物蓄积,可激活终末糖基化产物(advanced glycosylation end products, AGEs)-终末糖基化产物受体(receptor of advanced glycosylation end products,RAGE)途径,参与慢性肾脏病(chronic kidney disease,CKD)患者血管硬化的过程,而RAGE的剪接变体-内源性可溶性终末糖基化产物受体(endogenous secretory soluble form of advanced glycation end products receptor,esRAGE)可竞争性地结合AGEs,因此对此过程有保护作用。但此途径是否也参与了慢性肾脏病患者的左心室重构, esRAGE是否对慢性肾脏病患者左心室肥厚(Left ventricular hypertrophy,LVH)也具有一定的保护作用,目前尚不清楚。……
